Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Yasuaki Itoh

Kazunori Nishi

Kazuhiro Ogi

Nobuhiro Suzuki

Masataka Harada

Hideki Kizawa

Chieko Kitada

Masaaki Mori

Hideyuki Tanaka

Osamu Nishimura

Yukio Fujisawa

Koji Yoshimura

Shoichi Ohkubo

Hidetoshi Komatsu

Minoru Maruyama

Shinichi Mogi

Yuko Noguchi

Disclosed are compounds or their salts that promote or inhibit the activities of a protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, compounds or their salts that promote or inhibit the activities of a gene for the protein, antisense polynucleotides comprising the whole or part of a base sequence complimentary or substantially complimentary to the base sequence of a polynucleotide encoding the protein or its partial peptide, antibodies to the protein, etc. These compounds or their salts, antisense nucleotides, antibodies, etc. can be used as agents for the prevention/treatment of mental disorders, prolactin-related disorders, etc.

Screening methods using GPR52

The present invention relates to antibodies that bind to the A chain N-terminal peptide. The present invention also relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt., (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.

Antibodies to insulin/IGF/relaxin family polypeptides

The present invention relates to amino acid sequences for novel tachykinin polypeptides and base sequences encoding them, agonists and antagonists of such polypeptides, pharmaceutical compositions comprising them, and the like.

Tachykinin-like polypeptides and use thereof

The present invention relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt, (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.

Insulin/IGF/relaxin family polypeptides and DNAS thereof

The present invention relates to novel secretory polypeptides and precursor proteins thereof, which show a high homology to MIA (melanoma inhibitor activity)/CD-RAP (bovine cartilage-derived retinoic acid-sensitive protein); are specifically expressed in the cartilage tissue; and have an effect on the cartilage differentiation. The polypeptides and the DNAs encoding the same can be used for the diagnosis, treatment, or prevention of bone and joint diseases or pathological angiogenesis. As well, the polypeptides are useful as a reagent for screening a compound that promotes or inhibits the activity of the polypeptides. The antibody to the polypeptides can be used for the detection, quantification, or neutralization of the polypeptide in a test sample fluid. Further by using the promoter of the present invention, a therapeutic protein can be expressed predominantly in the cartilage tissue for a gene therapy.

Polypeptide and DNA thereof

Assays for an anti-pre-S antibody in a human serum by an enzyme immunoassay in which a biotin-avidin system is used are disclosed. The assays include inhibition method, sandwich method, competitive method and Protein A or anti-human IgG antibody method in a solid phase. The assays can determine the anti-pre-S antibody titer in human sera highly sensitively and simply without use of radioactive materials.

Assay for anti-pre-S antibody

Growing community of inventors

Tsuchiura, Japan

Yasuaki Itoh